Loading...

Molecular Templates

DB:NZW2
Snowflake Description

Excellent balance sheet and fair value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
NZW2
DB
$231M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Molecular Templates, Inc., a clinical stage oncology company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other diseases. The last earnings update was 23 days ago. More info.


Add to Portfolio Compare Print
  • Molecular Templates has significant price volatility in the past 3 months.
NZW2 Share Price and Events
7 Day Returns
-6.8%
DB:NZW2
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
-24.2%
DB:NZW2
-10.2%
DE Biotechs
-6%
DE Market
NZW2 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Molecular Templates (NZW2) -6.8% 7% 46.4% -24.2% - -
DE Biotechs -2.4% 3.2% -7.7% -10.2% 51.2% 10.1%
DE Market 1.8% 4.6% 7.4% -6% 10.1% 15.3%
1 Year Return vs Industry and Market
  • NZW2 underperformed the Biotechs industry which returned -10.2% over the past year.
  • NZW2 underperformed the Market in Germany which returned -6% over the past year.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Molecular Templates undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Molecular Templates to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Molecular Templates.

DB:NZW2 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 3 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:NZW2
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.45
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.448 (1 + (1- 21%) (1.41%))
1.311
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.31
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.311 * 5.96%)
8.04%

Discounted Cash Flow Calculation for DB:NZW2 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Molecular Templates is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:NZW2 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 8.04%)
2019 -31.90 Analyst x1 -29.53
2020 -45.10 Analyst x1 -38.64
2021 -48.70 Analyst x1 -38.62
2022 -21.70 Analyst x1 -15.93
2023 54.70 Analyst x1 37.16
2024 84.13 Est @ 53.8% 52.90
2025 115.87 Est @ 37.73% 67.43
2026 146.55 Est @ 26.48% 78.94
2027 173.81 Est @ 18.6% 86.66
2028 196.57 Est @ 13.09% 90.71
Present value of next 10 years cash flows $291.10
DB:NZW2 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $196.57 × (1 + 0.23%) ÷ (8.04% – 0.23%)
$2,521.91
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $2,521.91 ÷ (1 + 8.04%)10
$1,163.80
DB:NZW2 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $291.10 + $1,163.80
$1,454.89
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $1,454.89 / 36.74
$39.6
DB:NZW2 Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:NZW2 represents 0.84857x of NasdaqCM:MTEM
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.84857x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 39.60 x 0.84857
€33.61
Value per share (EUR) From above. €33.61
Current discount Discount to share price of €5.33
= -1 x (€5.33 - €33.61) / €33.61
84.1%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Molecular Templates is available for.
Intrinsic value
>50%
Share price is €5.33 vs Future cash flow value of €33.61
Current Discount Checks
For Molecular Templates to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Molecular Templates's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Molecular Templates's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Molecular Templates's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Molecular Templates's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:NZW2 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-1.02
NasdaqCM:MTEM Share Price ** NasdaqCM (2019-04-18) in USD $6.28
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Molecular Templates.

DB:NZW2 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:MTEM Share Price ÷ EPS (both in USD)

= 6.28 ÷ -1.02

-6.14x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Molecular Templates is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Molecular Templates is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Molecular Templates's expected growth come at a high price?
Raw Data
DB:NZW2 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -6.14x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
-17%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Molecular Templates, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Molecular Templates's assets?
Raw Data
DB:NZW2 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $2.75
NasdaqCM:MTEM Share Price * NasdaqCM (2019-04-18) in USD $6.28
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:NZW2 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:MTEM Share Price ÷ Book Value per Share (both in USD)

= 6.28 ÷ 2.75

2.29x

* Primary Listing of Molecular Templates.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Molecular Templates is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Molecular Templates's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Molecular Templates has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Molecular Templates expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-17%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Molecular Templates expected to grow at an attractive rate?
  • Unable to compare Molecular Templates's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Molecular Templates's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Molecular Templates's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:NZW2 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:NZW2 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts -17%
DB:NZW2 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 22.9%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:NZW2 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:NZW2 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 44 -76 2
2022-12-31 23 -57 2
2021-12-31 10 -58 2
2020-12-31 16 -45 3
2019-12-31 15 -34 3
DB:NZW2 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 13 -4 -30
2018-09-30 9 -32 -31
2018-06-30 3 -26 -36
2018-03-31 2 -21 -31
2017-12-31 3 -14 -24
2017-09-30 3 -7 -20
2017-06-30 2 -6 -13
2017-03-31 3 -10 -11
2016-12-31 2 -9 -13

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Molecular Templates is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Molecular Templates's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:NZW2 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Molecular Templates Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:NZW2 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -0.90 -0.37 -1.43 2.00
2022-12-31 -1.17 -1.05 -1.29 2.00
2021-12-31 -1.26 -1.17 -1.35 2.00
2020-12-31 -1.13 -0.94 -1.38 3.00
2019-12-31 -0.93 -0.81 -1.09 4.00
DB:NZW2 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -1.02
2018-09-30 -1.13
2018-06-30 -1.47
2018-03-31 -1.72
2017-12-31 -2.11
2017-09-30 -4.31
2017-06-30 -41.61
2017-03-31 -37.89
2016-12-31 -59.04

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Molecular Templates will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Molecular Templates's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Molecular Templates has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Molecular Templates performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Molecular Templates's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Molecular Templates does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Molecular Templates's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Molecular Templates's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Molecular Templates's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Molecular Templates Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:NZW2 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 13.29 -30.29 14.08
2018-09-30 9.42 -30.57 13.69
2018-06-30 3.32 -36.43 12.15
2018-03-31 1.99 -31.19 10.87
2017-12-31 3.40 -24.10 9.76
2017-09-30 2.93 -20.14 8.16
2017-06-30 2.28 -12.62 6.50
2017-03-31 3.21 -11.49 5.49
2016-12-31 1.88 -12.60 4.48
2015-12-31 0.53 -6.99 2.57

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Molecular Templates has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Molecular Templates has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Molecular Templates improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Molecular Templates's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Molecular Templates has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Molecular Templates's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Molecular Templates's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Molecular Templates is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Molecular Templates's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Molecular Templates's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 32.2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Molecular Templates Company Filings, last reported 3 months ago.

DB:NZW2 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 100.91 3.25 97.96
2018-09-30 106.19 3.16 78.74
2018-06-30 62.18 3.06 41.65
2018-03-31 70.94 3.00 49.28
2017-12-31 77.29 3.48 58.91
2017-09-30 87.90 4.19 68.18
2017-06-30 -19.09 18.76 4.61
2017-03-31 -15.05 16.74 2.94
2016-12-31 -13.89 12.88 1.72
2015-12-31 -2.98 5.68 4.24
  • Molecular Templates's level of debt (3.2%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Molecular Templates's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Molecular Templates has sufficient cash runway for more than 3 years based on current free cash flow.
  • Molecular Templates has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 51.9% each year.
X
Financial health checks
We assess Molecular Templates's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Molecular Templates has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Molecular Templates's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Molecular Templates dividends.
If you bought €2,000 of Molecular Templates shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Molecular Templates's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Molecular Templates's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:NZW2 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:NZW2 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Molecular Templates has not reported any payouts.
  • Unable to verify if Molecular Templates's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Molecular Templates's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Molecular Templates has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Molecular Templates's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Molecular Templates afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Molecular Templates has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Molecular Templates's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Eric Poma
COMPENSATION $606,536
AGE 46
TENURE AS CEO 10.3 years
CEO Bio

Dr. Eric E. Poma, Ph.D., is the Chief Executive Officer and Chief Scientific Officer of Molecular Templates, Inc. since 2009 and served as it's President. Dr. Poma served as Vice President of Business Development and Secretary at CytRx Oncology Corporation (formerly Innovive Pharmaceuticals, Inc.). Dr. Poma served as Assistant Vice President for Business Development of ImClone Systems, Inc. from June 2001 to March 2005, where he was responsible for all licensing and partnership agreements. He also ran the Strategic Planning group at ImClone before his appointment to Business Development. Prior to ImClone, he was a Healthcare and Biotechnology analyst for Eagle Growth Investors from july 2000 to June 2001. He serves as a Director at Molecular Templates, Inc. He held a variety of positions at Bates Healthworld (marketing and contract sales), Rood Research (market research) and Cline, Davis & Mann (pharmaceutical advertising). He holds a PhD in Microbiology and Immunology from the University of North Carolina at Chapel Hill, School of Medicine. He holds an MBA from the Leonard N. Stern School of Business at New York University and a Bachelor of Science in biology from the University of North Carolina at Chapel Hill.

CEO Compensation
  • Eric's compensation has increased whilst company is loss making.
  • Insufficient data for Eric to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Molecular Templates management team in years:

1.4
Average Tenure
43
Average Age
  • The average tenure for the Molecular Templates management team is less than 2 years, this suggests a new team.
Management Team

Eric Poma

TITLE
CEO, Chief Scientific Officer & Director
COMPENSATION
$607K
AGE
46
TENURE
10.3 yrs

Jason Kim

TITLE
President & COO
COMPENSATION
$445K
AGE
43
TENURE
9.3 yrs

Adam Cutler

TITLE
Chief Financial Officer
AGE
43
TENURE
1.4 yrs

Kurt Elster

TITLE
Executive Vice President of Corporate Development
AGE
51

Jack Higgins

TITLE
Executive VP of Operations & Head of Manufacturing
AGE
38

Erin Willert

TITLE
Executive Vice President of R&D
AGE
36

Jen-Sing Liu

TITLE
Executive Vice President of Manufacturing
AGE
55

Nenad Sarapa

TITLE
Senior Vice President of Clinical Development
TENURE
1.4 yrs

Conrad Jordaan

TITLE
Senior Vice President of Finance & Corporate Controller
TENURE
1.4 yrs

Roger Waltzman

TITLE
Chief Medical Officer
TENURE
0.2 yrs
Board of Directors Tenure

Average tenure and age of the Molecular Templates board of directors in years:

1.7
Average Tenure
48
Average Age
  • The average tenure for the Molecular Templates board of directors is less than 3 years, this suggests a new board.
Board of Directors

Barry Selick

TITLE
Chairman
AGE
64

Eric Poma

TITLE
CEO, Chief Scientific Officer & Director
COMPENSATION
$607K
AGE
46

Kevin Lalande

TITLE
Director
AGE
46

David Hoffmann

TITLE
Director
AGE
73
TENURE
1.7 yrs

Michel Klein

TITLE
Member of Scientific Advisory Board
AGE
80

Burkhard Jansen

TITLE
Member of Scientific Advisory Board

Neil Berinstein

TITLE
Member of Scientific Advisory Board

David Hirsch

TITLE
Director
AGE
48
TENURE
1.7 yrs

Scott Morenstein

TITLE
Director
AGE
42
TENURE
1.7 yrs

Jonathan Lanfear

TITLE
Director
TENURE
0.9 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
28. Dec 18 Buy Caxton Associates LP Company 26. Dec 18 26. Dec 18 25,000 €3.02 €75,598
27. Sep 18 Buy Caxton Associates LP Company 25. Sep 18 25. Sep 18 545,454 €4.67 €2,548,497
25. Sep 18 Buy Longitude Capital Management Co., LLC Company 21. Sep 18 21. Sep 18 365,000 €4.68 €1,708,583
X
Management checks
We assess Molecular Templates's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Molecular Templates has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Molecular Templates, Inc., a clinical stage oncology company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other diseases. The company primarily develops a pipeline of engineered toxin bodies. Its lead drug candidate is MT-3724 that is in a Phase II clinical trial for the treatment of relapsed/refractory diffuse large B-cell lymphoma; and Phase II clinical trial for treating non-Hodgkin’s lymphoma. The company also develops MT-4019, engineered toxin body targeting CD38; and TAK-169 targeting CD38. It has an agreement with Takeda Pharmaceutical Company Limited to develop CD38-targeted engineered toxin bodies for the treatment of patients with diseases, such as multiple myeloma. Molecular Templates, Inc. is headquartered in Austin, Texas.

Details
Name: Molecular Templates, Inc.
NZW2
Exchange: DB
Founded:
$205,140,356
36,736,012
Website: http://www.mtem.com
Address: Molecular Templates, Inc.
9301 Amberglen Boulevard,
Suite 100,
Austin,
Texas, 78729,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM MTEM New Common Shares Nasdaq Capital Market US USD 03. Aug 2017
DB NZW2 New Common Shares Deutsche Boerse AG DE EUR 03. Aug 2017
Number of employees
Current staff
Staff numbers
68
Molecular Templates employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/21 22:00
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/03
Last earnings filing: 2019/03/29
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.